G1 Therapeutics, Inc. (GTHX) financial statements (2021 and earlier)

Company profile

Business Address 700 PARK OFFICES DRIVE
RESEARCH TRIANGLE PARK, NC 27709
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments207238234242269300325
Cash and cash equivalents207238234242269300325
Restricted cash and investments000000 
Receivables0      
Other undisclosed current assets9761233
Total current assets:216246240244271303328
Noncurrent Assets
Operating lease, right-of-use asset888910101
Property, plant and equipment2333442
Regulated entity, other noncurrent assets111    
Other undisclosed noncurrent assets1110001
Total noncurrent assets:1213141314143
TOTAL ASSETS:229258254257285317332
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities20182117192118
Accounts payable4235473
Accrued liabilities16161813151414
Deferred revenue014     
Other liabilities3111100
Total current liabilities:23332218202118
Noncurrent Liabilities
Long-term debt and lease obligation888910101
Operating lease, liability888910101
Other undisclosed noncurrent liabilities121211    
Total noncurrent liabilities:202828910101
Total liabilities:51615027293119
Stockholders' equity
Stockholders' equity attributable to parent177197204229256286313
Common stock0000000
Treasury stock, value(0)(0)(0)(0)(0)(0)(0)
Additional paid in capital613608603597592588582
Accumulated deficit(436)(411)(399)(368)(337)(301)(269)
Total stockholders' equity:177197204229256286313
TOTAL LIABILITIES AND EQUITY:229258254257285317332

Income statement (P&L) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Gross profit:17272    
Operating expenses(41)(36)(33)(32)(37)(34)(33)
Operating loss:(24)(10)(31)(32)(37)(34)(33)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
(1)(1)(0)1122
Interest and debt expense(0)      
Other undisclosed income from continuing operations before equity method investments, income taxes0      
Loss from continuing operations before income taxes:(25)(11)(31)(31)(35)(32)(31)
Income tax expense(0)(1)     
Net loss available to common stockholders, diluted:(25)(12)(31)(31)(35)(32)(31)

Comprehensive Income ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net loss:(25)(12)(31)(31)(35)(32)(31)
Comprehensive loss, net of tax, attributable to parent:(25)(12)(31)(31)(35)(32)(31)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: